N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction? | Zendy

Maria Teresa Sandri | Zendy; Michela Salvatici | Zendy; Daniela Cardinale | Zendy; Laura Zorzino | Zendy; Rita Passerini | Zendy; Paola Lentati | Zendy; María Isabel León | Zendy; Maurizio Civelli | Zendy; Giovanni Martinelli | Zendy; Carlo M. Cipolla | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

N-Terminal Pro-B-Type Natriuretic Peptide after High-Dose Chemotherapy: A Marker Predictive of Cardiac Dysfunction?

Author(s) -

Maria Teresa Sandri,

Michela Salvatici,

Daniela Cardinale,

Laura Zorzino,

Rita Passerini,

Paola Lentati,

María Isabel León,

Maurizio Civelli,

Giovanni Martinelli,

Carlo M. Cipolla

Publication year - 2005

Publication title -

clinical chemistry

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.705

H-Index - 218

eISSN - 1530-8561

pISSN - 0009-9147

DOI - 10.1373/clinchem.2005.050153

Subject(s) - medicine , natriuretic peptide , isovolumetric contraction , ejection fraction , heart failure , cardiology , chemotherapy , diastole , predictive marker , endocrinology , blood pressure , cancer

Chronic cardiac dysfunction may develop after administration of aggressive chemotherapy, sometimes leading to development of congestive heart failure (CHF). Recently, N-terminal pro-B-type natriuretic peptide (NT-proBNP) was implicated as a marker of CHF. In this study we evaluated the predictive role of NT-proBNP in patients treated with high-dose chemotherapy (HDC).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research